Clinical Trial Update: Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial in China evaluating autologous stem cell transplantation combined with BCMA CAR-T therapy for ultra high risk multiple myeloma. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• BCMA CAR-T

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk | Phase 1, Phase 2 | Status: RECRUITING